Last checked at 
| Director Dealings Summary - Week Ended April 2 | ||||||||||||
| Company | Name | Position | Number of Shares | Resulting Holding | *Note | GBP Value | ||||||
| BUYS | ||||||||||||
| RM2 International | John Walsh | CEO | 1.2 million | 22.2 million | 648,000 | |||||||
| London Capital Group | Charles-Henri Sabet | CEO | 125,000 | 6.9 million | 340,000 | |||||||
| Hutchison China | Simon To | Chairman | 18,000 | 69,000 | Same day as concept trial for cancer treatment met efficacy target. | 234,000 | ||||||
| Hutchison China | Edith Shih | Non-Executive | 18,000 | 48,000 | Same day as concept trial for cancer treatment met efficacy target. | 234,000 | ||||||
| Standard Life UK Smaller Co's | Allister Langlands | Director | 50,000 | 95,000 | 145,000 | |||||||
| Koovs | Waheed Alli | Chairman | 152,500 | 4.9 million | Same day as Koovs said it would spend more on marketing than anticapted. | 99,000 | ||||||
| Walker Crips | Sean Kin Wai Lam | MD | 221,000 | 422,996 | 95,000 | |||||||
| Walker Crips | Lim Hua Min | Non-Executive | 221,000 | 9.1 million | 95,000 | |||||||
| Monitise | Elizabth Buse | CEO | 500,000 | 1 million | One week after Monitise said it was no longer for sale deciding to remain an independent company. | 66,000 | ||||||
| Stanley Gibbons | Martin Bralsford | Chairman | 22,000 | 204,800 | Same day as profit warning. | 52,000 | ||||||
| Diploma | Andrew Smith | Non-Executive | 5,500 | Undisclosed | 45,000 | |||||||
| Indivior | Shaun Thaxter | CEO | 20,000 | 500,000 | 39,000 | |||||||
| Monitise | Tim Wade | Non-Executive | 250,000 | 350,000 | One week after Monitise said it was no longer for sale deciding to remain an independent company. | 35,000 | ||||||
| 7digital | Donald Cruickshank | Chairman | 140,000 | 290,000 | 24,000 | |||||||
| Synectics | David Coghlan | Chairman | 20,000 | 1.5 million | 23,000 | |||||||
| Plant Impact | John Brubaker | CEO | 40,000 | 646,000 | 21,000 | |||||||
| Mission Marketing | David Morgan | Chairman | 40,000 | 6.1 million | 17,000 | |||||||
| PuriCore | Charles Spicer | Chairman | 50,610 | 75,000 | 16,000 | |||||||
| Inspirit Energy | John Gunn | CEO | 2 million | 355 million | Same day as Inspirit said it will deliver its first micro-combined heat and power boiler to a major utility. | 13,000 | ||||||
| Barclays | John McFarlane | Incoming Chairman | 5,000 | 6,015 | Will become chairman at AGM on April 23. | 12,000 | ||||||
| LPA Goup | Per Staehr | Non-Executive | 15,000 | 185,500 | 11,000 | |||||||
| Progility | Hugh Crawley | CFO | 200,000 | 200,000 | Appointed last Friday. | 11,000 | ||||||
| superGroup | Euan Sutherland | CEO | 10,117 | 11,613 | 9,900 | |||||||
| Lavendon | John Coghlan | Non-Executive | 5,000 | 5,500 | 9600 | |||||||
| Aeorema Communications | Michael Hale | Chairman | 25,000 | 1.7 million | 6,900 | |||||||
| Churchill China | David Taylor | CFO | 1,000 | 21,000 | 6,000 | |||||||
| SOCO International | Anthony Maris | COO | 1,213 | 132,956 | 1,900 | |||||||
| SELLS | ||||||||||||
| Nostrum Oil & Gas | Frank Monstrey | Chairman | 18.7 million | 32.5 million | 2 days after Nostrum reported profit drop. | 109,000,000 | ||||||
| NAHL Group | Samantha Porteous | Non-Executive Director | 3.1 million | Nil | 3 days after NAHL reported profit drop in maiden results. | 7,600,000 | ||||||
| IHG | Tracy Robbins | Director | 28,047 | 183,997 | 738,000 | |||||||
| Michael Page | Oliver Watson | Director | 101,620 | Undisclosed | 540,000 | |||||||
| Jupiter Fund Management | Adrian Creedy | Company Secretary | 100,000 | 1.8 million | 414,000 | |||||||
| STV Group | Rob Woodward | CEO | 100,000 | 419,322 | 383,000 | |||||||
| Nichols | Peter Nichols | Chairman | 17,060 | 2.1 million | 201,000 | |||||||
| Tribal Group | Steve Breach | Finance Director | 81,296 | 172,728 | 2 weeks after Tribal swung to a loss. | 120,000 | ||||||
| Witan Investment Trust | Harry Henderson | Chairman | 2,100 | 722,732 | 17,000 | |||||||
| *Note: A recent company event around the time of the dealing does not suggest the dealing took place because of that event. When a spouse or related party to a director buys shares, the resulting holding is the beneficial holding of the director | ||||||||||||
| Contact: +44 207 199 0340; newsroom@alliancenews.com; @AllNewsTeam | ||||||||||||
| Copyright 2015 Alliance News Limited. All Rights Reserved. | ||||||||||||
27 Feb 2023 11:39
Hutchmed enrols last patient in lymphoma treatment trial
(Sharecast News) - Hutchmed China announced the completion of patient enrollment in a phase two registration trial of 'amdizalisib' on Monday, for the treatment of relapsed or refractory follicular lymphoma (FL), which is a subtype of non-Hodgkin's lymphoma.
Read more